Cytosorbents (CTSO) Invested Capital (2016 - 2025)
Cytosorbents (CTSO) has disclosed Invested Capital for 14 consecutive years, with $24.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital rose 79.48% year-over-year to $24.0 million, compared with a TTM value of $24.0 million through Sep 2025, up 79.48%, and an annual FY2024 reading of $11.1 million, down 61.06% over the prior year.
- Invested Capital was $24.0 million for Q3 2025 at Cytosorbents, up from $11.6 million in the prior quarter.
- Across five years, Invested Capital topped out at $77.3 million in Q1 2021 and bottomed at $11.1 million in Q4 2024.
- Average Invested Capital over 5 years is $36.4 million, with a median of $29.5 million recorded in 2023.
- The sharpest move saw Invested Capital skyrocketed 112.24% in 2021, then crashed 61.06% in 2024.
- Year by year, Invested Capital stood at $62.6 million in 2021, then plummeted by 43.47% to $35.4 million in 2022, then decreased by 19.37% to $28.5 million in 2023, then plummeted by 61.06% to $11.1 million in 2024, then surged by 116.26% to $24.0 million in 2025.
- Business Quant data shows Invested Capital for CTSO at $24.0 million in Q3 2025, $11.6 million in Q2 2025, and $14.5 million in Q1 2025.